<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083380</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_13_003</org_study_id>
    <nct_id>NCT02083380</nct_id>
  </id_info>
  <brief_title>Phase II Efficacy Study of Artefenomel &amp; Piperaquine in Adults &amp; Children With P. Falciparum Malaria.</brief_title>
  <official_title>Randomised Phase IIb Study of Efficacy, Safety, Tolerability &amp; Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability
      and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients
      &gt; 0.5 years and &lt;= 70 years of age with uncomplicated Plasmodium falciparum malaria in Africa
      and Asia (Vietnam).

      Interim analyses for futility were planned. Adults and children will be included through
      progressive step-down in age following safety review by an independent safety monitoring
      board (ISMB).

      If the study were to meets its efficacy objectives, this will inform dose setting for Phase
      III studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind single-dose (loose combination) study in the target patient
      population of children &gt; 0.5 years and &lt;= 5 years of age in Africa and patients of all ages
      in Asia (&gt; 0.5 years and &lt;= 70 years) with uncomplicated Plasmodium falciparum malaria.
      Patients &gt; 5 years in Africa were also to be recruited in a safety age step down procedure.
      The underlying assumption was that children of 5 years or less in Africa and all ages in Asia
      will have a higher probability of having lower immunity and hence potentially require higher
      drug exposure to achieve efficacy and hence the study aimed to recruit 60-80% African
      children &lt; = 5 years and 18-36% Asian patients (defined as the target population) and
      approximately 10% African patients &gt;5 years,

      Three OZ439/PQP treatment arms were to be included for patients &gt;= 35 kg (800mg OZ439 in
      loose combination with PQP doses of either 640, 960, 1440 mg). Doses were scaled for patients
      &lt; 35kg based on the weight to achieve similar exposures in patients &gt;= 35kg.

      The study was to test for futility and dose arms were to be dropped if the probability was
      &gt;30% that PCR-adjusted ACPR at Day 28 (ACPR28) was less than 90% (the target efficacy for the
      study was &gt;= 95% ACPR28). Only data from patients in Asia patients and Africa patients &lt; 5
      years were to be included in the Interim analysis, although all patients were to be included
      in the final analysis. Interim analyses were to occur after recruitment of approximately 50
      evaluable patients per dose cohort and thereafter approximately after every 25 patients.

      In a separate process, the safety of OZ439/PQP treatment arms was to be assessed at scheduled
      time points by an ISMB and adults and children were included through progressive step-down in
      age range following safety evaluation

      Following Screening and informed consent, patients were to receive study drug and were to be
      followed for clinical signs of malaria (parasitaemia and temperature), safety assessments and
      pharmacokinetics up to Day 42 following dosing (Day 63 at selected sites).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)</measure>
    <time_frame>Day 28</time_frame>
    <description>Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).
95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years)</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR - Adjusted ACPR at Day 42 in the PP Population</measure>
    <time_frame>Days 42</time_frame>
    <description>PCR - adjusted adequate clinical and parasitological response at Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-adjusted ACPR at Day 63 in the PP Population</measure>
    <time_frame>Day 63</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response at Day 63</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 28 in the PP Population</measure>
    <time_frame>Day 28</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 42 in the PP Population</measure>
    <time_frame>Day 42</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 63 in the PP Population</measure>
    <time_frame>Day 63</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 63</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-adjusted ACPR at Day 28 in the ITT Population</measure>
    <time_frame>Day 28</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response at Day 28. Intent to Treat ( ITT) population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-adjusted ACPR at Day 42 in the ITT Population</measure>
    <time_frame>Day 42</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR-adjusted ACPR at Day 63 in the ITT Population</measure>
    <time_frame>Day 63</time_frame>
    <description>PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 28 in the ITT Population</measure>
    <time_frame>Day 28</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 28 in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 42 in the ITT Population</measure>
    <time_frame>Day 42</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 42 in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR at Day 63 in the ITT Population</measure>
    <time_frame>Day 63</time_frame>
    <description>Crude adequate clinical and parasitological response at Day 63 in the ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Recurrence</measure>
    <time_frame>Day 63</time_frame>
    <description>Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Recrudescence</measure>
    <time_frame>Day 63</time_frame>
    <description>Kaplan-Meier estimate of number of patients with recrudescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of New Infection Rate</measure>
    <time_frame>Day 63</time_frame>
    <description>Kaplan-Meier estimate of number of patients with new infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>0, 6, 12, 18, 24, 30, 36, 48 and 72 hours post dose</time_frame>
    <description>Time post dose to parasite clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Day 42</time_frame>
    <description>Time to fever clearance (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRR48</measure>
    <time_frame>0, 6, 12, 18, 24, 30, 36 and 48 hours post dose</time_frame>
    <description>Parasite reduction ratio at 48 hours post dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Piperaquine: Cday7 Asia (All Ages)</measure>
    <time_frame>Day 7</time_frame>
    <description>Piperaquine concentration at Day7 in Asian patients all ages</description>
  </other_outcome>
  <other_outcome>
    <measure>Piperaquine: Cday7 Africa (&gt; 5 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Piperaquine concentration at Day7 in African patients &gt; 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Piperaquine: Cday7 Africa (&gt;2 to &lt;= 5 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Piperaquine concentration at Day7 in African patients &gt; 2 and &lt;= 5years</description>
  </other_outcome>
  <other_outcome>
    <measure>Piperaquine: Cday7 Africa (&gt;=0.5 to &lt;= 2 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Piperaquine concentration at Day7 in African patients &gt;= 0.5 and &lt;= 2 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Artefenomel Cday7 Asian Patients (All Ages)</measure>
    <time_frame>Day 7</time_frame>
    <description>Artefenomel concentration on Day 7 in Asian Patients (all ages). All Treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Artefenomel Cday7 African Patients (&gt; 5 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Artefenomel concentration on Day 7 in African Patients &gt; 5 years. All Treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Artefenomel Cday7 African Patients (&gt;2 to &lt;= 5 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Artefenomel concentration on Day 7 in African Patients &gt;2 to &lt;= 5 years. All Treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Artefenomel Cday7 African Patients (&gt;=0.5 to &lt;= 2 Years)</measure>
    <time_frame>Day 7</time_frame>
    <description>Artefenomel concentration on Day 7 in African Patients &gt;= 0.5 to &lt;=2 years. All Treatment arms.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Uncomplicated Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>A) Artefenomel 800mg: piperaquine 640mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B) Artefenomel 800mg: piperaquine 960mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) Artefenomel 800mg: piperaquine 1440mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artefenomel 800mg: piperaquine 640mg</intervention_name>
    <description>Active, loose combination</description>
    <arm_group_label>A) Artefenomel 800mg: piperaquine 640mg</arm_group_label>
    <other_name>OZ439 ; PQP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artefenomel 800mg: piperaquine 960mg</intervention_name>
    <description>Active, loose combination</description>
    <arm_group_label>B) Artefenomel 800mg: piperaquine 960mg</arm_group_label>
    <other_name>OZ439 ; PQP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artefenomel 800mg: piperaquine 1440mg</intervention_name>
    <description>Active, loose combination</description>
    <arm_group_label>C) Artefenomel 800mg: piperaquine 1440mg</arm_group_label>
    <other_name>OZ439 ; PQP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient age &gt;6 months &lt;70 years.

          2. Body weight &gt;5 kg &lt;90 kg.

          3. Presence of mono-infection of P. falciparum with:

               1. Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic
                  temperature ≥ 38°C, or history of fever in the previous 24 hours (history of
                  fever must be documented) and,

               2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual
                  parasites /µL of blood.

          4. Written informed consent provided by the adult patient, or parent or legally
             acceptable representative (LAR) of the minor patient or by an impartial witness (if
             the patient or patient's LAR is illiterate), and by the medically qualified
             Investigator. Children will be asked to provide assent where appropriate. The age from
             which this will be sought will be defined by local legislation.

        Exclusion Criteria:

          1. Presence of severe malaria (according to World Health Organization (WHO) definition -
             WHO 2013)

          2. Anti-malarial treatment:

               1. With piperaquine -based compound, mefloquine, naphthoquine or
                  sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their
                  inhibition of new infections has fallen below 50%).

               2. With amodiaquine or chloroquine within the previous 4 weeks.

               3. With quinine, halofantrine, lumefantrine-based compounds and any other
                  anti-malarial treatment or antibiotics with anti-malarial activity (including
                  cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin)
                  within the past 14 days.

               4. With any herbal products or traditional medicines, within the past 7 days.

          3. Known history or evidence of clinically significant disorders such as, respiratory
             (including active tuberculosis), hepatic, renal, gastrointestinal, immunological,
             neurological (including auditory), endocrine, infectious, malignancy, psychiatric,
             history of convulsions or other abnormality (including head trauma).

          4. Family history of sudden death or of congenital or clinical conditions known to
             prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac
             arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.

          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.

          6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left
             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac
             failure accompanied by reduced left ventricle ejection fraction.

          7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.

          8. Any treatment which can induce a lengthening of QT interval, such as:

               1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,
                  procainamide, quinidine, hydroquinidine, sotalol),

               2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,
                  haloperidol, mesoridazine, pimozide, or thioridazine),

               3. Anti-depressive agents, certain antimicrobial agents, including agents of the
                  following classes macrolides (e.g. erythromycin, clarithromycin),
                  fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole
                  antifungal agents, and also pentamidine and saquinavir,

               4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine),
                  cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
                  methadone, vinca alkaloids, arsenic trioxide.

               5. Anti-emetics with known QT prolongation potential such as domperidone

          9. Mixed Plasmodium infection

         10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment
             in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3
             or more watery stools per day

         11. Severe malnutrition (defined for subjects aged ten years or less as the
             weight-for-height being below -3 standard deviation or less than 70% of median of the
             National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for
             subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP
             Manual, Chapter 1)).

         12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or
             other aminoquinolones or to OZ439 or OZ277

         13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or
             Hepatitis C antibody (HCV Ab).

         14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate
             transaminase (AST)/ Alanine transaminase (ALT) ≥ 2x Upper limit of normal (ULN).

         15. If Total Bilirubin is &gt; 1 and ≤ 1.5xULN, exclude the patient if AST/ALT &gt;1.5xULN.

         16. Total Bilirubin &gt; 1.5XULN

         17. Haemoglobin level below 8 g/dL.

         18. Serum creatinine levels ≥2 x ULN

         19. Female patients of child bearing potential must be neither pregnant (as demonstrated
             by a negative pregnancy test) nor lactating, and must be willing to take measures not
             to become pregnant during the study period and safety follow-up period.

         20. Have received an investigational drug within the past 4 weeks.

         21. Previous participation in any malaria vaccine study or received malaria vaccine in any
             other circumstance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona Macintyre, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicines for Malaria Venture (MMV)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ramharter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CERMEL (Centre de Recherches Médicale de Lambaréné)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre D'Étude Et de Recherchesur Le Paludisme Associé À La Grossesse Et À L'Enfance (Cerpage) Cerpage</name>
      <address>
        <city>Cotonou</city>
        <zip>FSS 01 BP 188</zip>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le paludisme (CNRFP) Ouagadougou, Kadiogo</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical research Unit of Nanoro (CRUN)/CMA Saint Camille de Nanoro, 11 BP 218 Ouagadougou CMS 11</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinshasa School of Public Health, School of Medicine University of Kinshasa</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherches Medicales de Lambarene, Albert Schweitzer Hospital</name>
      <address>
        <city>Lambarene</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>arielle K. Bouyou-Akotet, Department of Parasitology-Mycology and Tropical Medicine, Faculty of Medicine, Université des Sciences de la Santé, BP 4009, Libreville, Gabon</name>
      <address>
        <city>Libreville</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MANHIÇA HEALTH RESEARCH CENTER, Rua 12, Vila da Manhica, Maputa,</name>
      <address>
        <city>Chefe Maputa</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Malariology, Parasitology and Entomology, 245 Luong The Vinh Street, Trung van, Tu Liem, Hanoi, Vietnam</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Gabon</country>
    <country>Mozambique</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <results_first_submitted>December 5, 2016</results_first_submitted>
  <results_first_submitted_qc>December 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmodium falciparum malaria</keyword>
  <keyword>malaria</keyword>
  <keyword>OZ439</keyword>
  <keyword>piperaquine</keyword>
  <keyword>PQP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomized double blind study. Conduct was July 2014-August 2015 in Africa (Benin, Burkina Faso, Democratic Republic of Congo, Gabon, Mozambique and Uganda) and Vietnam. Following informed consent patients were recruited to the study. Patients below the age to give legal Informed Consent were consented according local customs / legal requirements.</recruitment_details>
      <pre_assignment_details>Patients were assigned a screening number and underwent screening procedures to assess eligibility. Eligible patients were randomized through an Interactive web-response system and followed for efficacy and safety up to 42 days post dose and 63 days at selected centers. Patients were consented separately to remain in the study up to Day 63.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
          <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
        </group>
        <group group_id="P2">
          <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
          <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
        </group>
        <group group_id="P3">
          <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
          <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148">5 subjects excluded from safety / ITT population - no drug administered</participants>
                <participants group_id="P2" count="151">3 subjects excluded from safety / ITT population - no drug administered</participants>
                <participants group_id="P3" count="149">3 subjects excluded from safety / ITT population - no drug administered</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A) Artefenomel 800mg: PQP 640mg</title>
          <description>Artefenomel 800mg: Piperaquine 640mg</description>
        </group>
        <group group_id="B2">
          <title>B) Artefenomel 800mg: PQP 960mg</title>
          <description>Artefenomel 800mg: Piperaquine 960mg</description>
        </group>
        <group group_id="B3">
          <title>C) Artefenomel 800mg: PQP 1440mg</title>
          <description>Artefenomel 800mg: Piperaquine 1440mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="143"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="146"/>
            <count group_id="B4" value="437"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt; 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 to &lt;= 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 to &lt;= 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 0.5 to &lt;= 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)</title>
        <description>Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).
95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: piperaquine 640mg: Active, loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)</title>
          <description>Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).
95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="61.13" upper_limit="79.19"/>
                    <measurement group_id="O2" value="68.4" lower_limit="59.13" upper_limit="76.66"/>
                    <measurement group_id="O3" value="78.6" lower_limit="70.09" upper_limit="85.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="42.52" upper_limit="82.03"/>
                    <measurement group_id="O2" value="64" lower_limit="42.52" upper_limit="82.03"/>
                    <measurement group_id="O3" value="70.4" lower_limit="49.82" upper_limit="86.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" lower_limit="61.81" upper_limit="82.13"/>
                    <measurement group_id="O2" value="69.6" lower_limit="59.10" upper_limit="78.73"/>
                    <measurement group_id="O3" value="81.1" lower_limit="71.49" upper_limit="88.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt; Than 5 Years)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="52.36" upper_limit="93.59"/>
                    <measurement group_id="O2" value="90.5" lower_limit="69.62" upper_limit="98.83"/>
                    <measurement group_id="O3" value="89.5" lower_limit="66.86" upper_limit="98.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&lt; = 5 Years)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="58.65" upper_limit="82.11"/>
                    <measurement group_id="O2" value="63.4" lower_limit="51.10" upper_limit="74.50"/>
                    <measurement group_id="O3" value="78.9" lower_limit="67.56" upper_limit="87.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;2 to &lt;= 5 Years)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" lower_limit="60.46" upper_limit="87.12"/>
                    <measurement group_id="O2" value="74.0" lower_limit="59.66" upper_limit="85.37"/>
                    <measurement group_id="O3" value="83.6" lower_limit="71.20" upper_limit="92.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years)</title>
        <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the PP Population: Africa (&gt;= 0.5 to &lt;= 2 Years)</title>
          <description>PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="35.75" upper_limit="82.70"/>
                    <measurement group_id="O2" value="38.1" lower_limit="18.11" upper_limit="61.56"/>
                    <measurement group_id="O3" value="62.5" lower_limit="35.43" upper_limit="84.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR - Adjusted ACPR at Day 42 in the PP Population</title>
        <description>PCR - adjusted adequate clinical and parasitological response at Day 42</description>
        <time_frame>Days 42</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR - Adjusted ACPR at Day 42 in the PP Population</title>
          <description>PCR - adjusted adequate clinical and parasitological response at Day 42</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="54.82" upper_limit="74.27"/>
                    <measurement group_id="O2" value="65.7" lower_limit="55.99" upper_limit="74.60"/>
                    <measurement group_id="O3" value="72.0" lower_limit="62.13" upper_limit="80.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-adjusted ACPR at Day 63 in the PP Population</title>
        <description>PCR-adjusted adequate clinical and parasitological response at Day 63</description>
        <time_frame>Day 63</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 63 in the PP Population</title>
          <description>PCR-adjusted adequate clinical and parasitological response at Day 63</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="46.49" upper_limit="68.60"/>
                    <measurement group_id="O2" value="58.9" lower_limit="48.02" upper_limit="69.16"/>
                    <measurement group_id="O3" value="69.0" lower_limit="58.02" upper_limit="78.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 28 in the PP Population</title>
        <description>Crude adequate clinical and parasitological response at Day 28</description>
        <time_frame>Day 28</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. The PP population comprised 93.3% of the randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>C) Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 28 in the PP Population</title>
          <description>Crude adequate clinical and parasitological response at Day 28</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. The PP population comprised 93.3% of the randomized population.</population>
          <units>% ACPR unadjusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" lower_limit="48.36" upper_limit="66.03"/>
                    <measurement group_id="O2" value="56.6" lower_limit="47.85" upper_limit="65.09"/>
                    <measurement group_id="O3" value="66.9" lower_limit="58.23" upper_limit="74.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 42 in the PP Population</title>
        <description>Crude adequate clinical and parasitological response at Day 42</description>
        <time_frame>Day 42</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 42 in the PP Population</title>
          <description>Crude adequate clinical and parasitological response at Day 42</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>% ACPR unajusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="39.09" upper_limit="57.07"/>
                    <measurement group_id="O2" value="48.5" lower_limit="39.79" upper_limit="57.29"/>
                    <measurement group_id="O3" value="51.5" lower_limit="42.62" upper_limit="60.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 63 in the PP Population</title>
        <description>Crude adequate clinical and parasitological response at Day 63</description>
        <time_frame>Day 63</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. The PP population comprised 93.3% of the randomized population.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 63 in the PP Population</title>
          <description>Crude adequate clinical and parasitological response at Day 63</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. The PP population comprised 93.3% of the randomized population.</population>
          <units>% ACPR unadjusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="32.92" upper_limit="51.71"/>
                    <measurement group_id="O2" value="39.3" lower_limit="30.62" upper_limit="48.59"/>
                    <measurement group_id="O3" value="49.1" lower_limit="39.74" upper_limit="58.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-adjusted ACPR at Day 28 in the ITT Population</title>
        <description>PCR-adjusted adequate clinical and parasitological response at Day 28. Intent to Treat ( ITT) population.</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 28 in the ITT Population</title>
          <description>PCR-adjusted adequate clinical and parasitological response at Day 28. Intent to Treat ( ITT) population.</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="45.32" upper_limit="62.21"/>
                    <measurement group_id="O2" value="55.4" lower_limit="47.02" upper_limit="63.57"/>
                    <measurement group_id="O3" value="65.1" lower_limit="56.75" upper_limit="72.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-adjusted ACPR at Day 42 in the ITT Population</title>
        <description>PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population</description>
        <time_frame>Day 42</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 42 in the ITT Population</title>
          <description>PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="38.47" upper_limit="55.37"/>
                    <measurement group_id="O2" value="48.6" lower_limit="40.36" upper_limit="56.99"/>
                    <measurement group_id="O3" value="50.0" lower_limit="41.62" upper_limit="58.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-adjusted ACPR at Day 63 in the ITT Population</title>
        <description>PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population</description>
        <time_frame>Day 63</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-adjusted ACPR at Day 63 in the ITT Population</title>
          <description>PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR PCR-adjusted</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="28.67" upper_limit="45.45"/>
                    <measurement group_id="O2" value="38.6" lower_limit="30.47" upper_limit="47.16"/>
                    <measurement group_id="O3" value="43.7" lower_limit="35.19" upper_limit="52.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 28 in the ITT Population</title>
        <description>Crude adequate clinical and parasitological response at Day 28 in the ITT population</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 28 in the ITT Population</title>
          <description>Crude adequate clinical and parasitological response at Day 28 in the ITT population</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR unadjusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="44.63" upper_limit="61.53"/>
                    <measurement group_id="O2" value="53.4" lower_limit="45.01" upper_limit="61.61"/>
                    <measurement group_id="O3" value="63.0" lower_limit="54.64" upper_limit="70.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 42 in the ITT Population</title>
        <description>Crude adequate clinical and parasitological response at Day 42 in the ITT population</description>
        <time_frame>Day 42</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 42 in the ITT Population</title>
          <description>Crude adequate clinical and parasitological response at Day 42 in the ITT population</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR unadjusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" lower_limit="35.77" upper_limit="52.59"/>
                    <measurement group_id="O2" value="44.6" lower_limit="36.43" upper_limit="52.98"/>
                    <measurement group_id="O3" value="46.6" lower_limit="38.29" upper_limit="55.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR at Day 63 in the ITT Population</title>
        <description>Crude adequate clinical and parasitological response at Day 63 in the ITT population</description>
        <time_frame>Day 63</time_frame>
        <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR at Day 63 in the ITT Population</title>
          <description>Crude adequate clinical and parasitological response at Day 63 in the ITT population</description>
          <population>Intent to Treat (ITT) population : all patients who provided written informed consent, were randomised, received the single dose combination of OZ439/PQP study drug (or part thereof), and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% ACPR unadjusted (crude)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="28.67" upper_limit="45.45"/>
                    <measurement group_id="O2" value="35.0" lower_limit="27.14" upper_limit="43.51"/>
                    <measurement group_id="O3" value="43.0" lower_limit="34.48" upper_limit="51.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Recurrence</title>
        <description>Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection)</description>
        <time_frame>Day 63</time_frame>
        <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Recurrence</title>
          <description>Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection)</description>
          <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% population recurring</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Recrudescence</title>
        <description>Kaplan-Meier estimate of number of patients with recrudescence</description>
        <time_frame>Day 63</time_frame>
        <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Arttefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Recrudescence</title>
          <description>Kaplan-Meier estimate of number of patients with recrudescence</description>
          <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% patients with recrudescence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="29.1"/>
                    <measurement group_id="O3" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of New Infection Rate</title>
        <description>Kaplan-Meier estimate of number of patients with new infections</description>
        <time_frame>Day 63</time_frame>
        <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of New Infection Rate</title>
          <description>Kaplan-Meier estimate of number of patients with new infections</description>
          <population>modified Intent to Treat (mITT) population : all patients who provided written informed consent, were randomised, were compliant with the single dose combination of OZ439/PQP study drug and had a confirmed positive blood film for P. falciparum asexual parasitaemia at inclusion.</population>
          <units>% population with new infection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="16.3"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time</title>
        <description>Time post dose to parasite clearance</description>
        <time_frame>0, 6, 12, 18, 24, 30, 36, 48 and 72 hours post dose</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time</title>
          <description>Time post dose to parasite clearance</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="36.0" upper_limit="36.1"/>
                    <measurement group_id="O2" value="36.0" lower_limit="36.0" upper_limit="36.1"/>
                    <measurement group_id="O3" value="36.1" lower_limit="36.0" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time</title>
        <description>Time to fever clearance (hours)</description>
        <time_frame>Day 42</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time</title>
          <description>Time to fever clearance (hours)</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRR48</title>
        <description>Parasite reduction ratio at 48 hours post dose</description>
        <time_frame>0, 6, 12, 18, 24, 30, 36 and 48 hours post dose</time_frame>
        <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. Subjects with sufficient data points to determine PRR48</population>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>PRR48</title>
          <description>Parasite reduction ratio at 48 hours post dose</description>
          <population>Primary analysis population was the per protocol population defined as all patients comprising the ITT set and without major protocol deviations. Including insufficient evidence of study indication, no baseline parasitemia and non-compliance with study drug administration. Subjects with sufficient data points to determine PRR48</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.120" lower_limit="6.900" upper_limit="12.970"/>
                    <measurement group_id="O2" value="9.300" lower_limit="7.660" upper_limit="13.340"/>
                    <measurement group_id="O3" value="8.690" lower_limit="6.850" upper_limit="12.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Piperaquine: Cday7 Asia (All Ages)</title>
        <description>Piperaquine concentration at Day7 in Asian patients all ages</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine: Cday7 Asia (All Ages)</title>
          <description>Piperaquine concentration at Day7 in Asian patients all ages</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="72"/>
                    <measurement group_id="O2" value="6.9" spread="61"/>
                    <measurement group_id="O3" value="9.3" spread="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Piperaquine: Cday7 Africa (&gt; 5 Years)</title>
        <description>Piperaquine concentration at Day7 in African patients &gt; 5 years</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine: Cday7 Africa (&gt; 5 Years)</title>
          <description>Piperaquine concentration at Day7 in African patients &gt; 5 years</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="113"/>
                    <measurement group_id="O2" value="8.8" spread="105"/>
                    <measurement group_id="O3" value="12.1" spread="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Piperaquine: Cday7 Africa (&gt;2 to &lt;= 5 Years)</title>
        <description>Piperaquine concentration at Day7 in African patients &gt; 2 and &lt;= 5years</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine: Cday7 Africa (&gt;2 to &lt;= 5 Years)</title>
          <description>Piperaquine concentration at Day7 in African patients &gt; 2 and &lt;= 5years</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="71"/>
                    <measurement group_id="O2" value="9.2" spread="87"/>
                    <measurement group_id="O3" value="10.9" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Piperaquine: Cday7 Africa (&gt;=0.5 to &lt;= 2 Years)</title>
        <description>Piperaquine concentration at Day7 in African patients &gt;= 0.5 and &lt;= 2 years</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: Piperaquine 640mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg loose combination</description>
          </group>
          <group group_id="O2">
            <title>B) Artefenomel 800mg: Piperaquine 960mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 960mg loose combination</description>
          </group>
          <group group_id="O3">
            <title>C) Artefenomel 800mg: Piperaquine 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine: Cday7 Africa (&gt;=0.5 to &lt;= 2 Years)</title>
          <description>Piperaquine concentration at Day7 in African patients &gt;= 0.5 and &lt;= 2 years</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="63"/>
                    <measurement group_id="O2" value="5.9" spread="70"/>
                    <measurement group_id="O3" value="9.0" spread="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Artefenomel Cday7 Asian Patients (All Ages)</title>
        <description>Artefenomel concentration on Day 7 in Asian Patients (all ages). All Treatment arms.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: PQP 640mg, 960mg &amp; 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg, 960mg &amp; 1440mg combined
Artefenomel 800mg: PQP 640mg, 960mg &amp; 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>Artefenomel Cday7 Asian Patients (All Ages)</title>
          <description>Artefenomel concentration on Day 7 in Asian Patients (all ages). All Treatment arms.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Artefenomel Cday7 African Patients (&gt; 5 Years)</title>
        <description>Artefenomel concentration on Day 7 in African Patients &gt; 5 years. All Treatment arms.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: PQP 640mg, 960mg &amp; 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg, 960mg &amp; 1440mg combined</description>
          </group>
        </group_list>
        <measure>
          <title>Artefenomel Cday7 African Patients (&gt; 5 Years)</title>
          <description>Artefenomel concentration on Day 7 in African Patients &gt; 5 years. All Treatment arms.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Artefenomel Cday7 African Patients (&gt;2 to &lt;= 5 Years)</title>
        <description>Artefenomel concentration on Day 7 in African Patients &gt;2 to &lt;= 5 years. All Treatment arms.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: PQP 640mg, 960mg &amp; 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg, 960mg &amp; 1440mg combined</description>
          </group>
        </group_list>
        <measure>
          <title>Artefenomel Cday7 African Patients (&gt;2 to &lt;= 5 Years)</title>
          <description>Artefenomel concentration on Day 7 in African Patients &gt;2 to &lt;= 5 years. All Treatment arms.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Artefenomel Cday7 African Patients (&gt;=0.5 to &lt;= 2 Years)</title>
        <description>Artefenomel concentration on Day 7 in African Patients &gt;= 0.5 to &lt;=2 years. All Treatment arms.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A) Artefenomel 800mg: PQP 640mg, 960mg &amp; 1440mg</title>
            <description>Artefenomel 800mg: Piperaquine phosphate 640mg, 960mg &amp; 1440mg combined</description>
          </group>
        </group_list>
        <measure>
          <title>Artefenomel Cday7 African Patients (&gt;=0.5 to &lt;= 2 Years)</title>
          <description>Artefenomel concentration on Day 7 in African Patients &gt;= 0.5 to &lt;=2 years. All Treatment arms.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening up to Day 63 post dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A) Artefenomel 800mg: PQP 640mg</title>
          <description>Artefenomel 800mg: Piperaquine phosphate 640mg</description>
        </group>
        <group group_id="E2">
          <title>B) Artefenomel 800mg: PQP 960mg</title>
          <description>Artefenomel 800mg: Piperaquine 960mg</description>
        </group>
        <group group_id="E3">
          <title>C) Artefenomel 800mg: PQP 1440mg</title>
          <description>Artefenomel 800mg: Piperaquine 1440mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminase elevation</sub_title>
                <description>Two reversible SAEs of possibly related reversible transaminase elevation in one subject</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hemoglobin drop &lt; 5 g/dL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="146"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="148"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="146"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="148"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>malaria</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="146"/>
                <counts group_id="E2" events="48" subjects_affected="45" subjects_at_risk="148"/>
                <counts group_id="E3" events="44" subjects_affected="43" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Plasmodium Falciparum Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiumgram QT prolonged</sub_title>
                <counts group_id="E1" events="56" subjects_affected="44" subjects_at_risk="146"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="148"/>
                <counts group_id="E3" events="29" subjects_affected="27" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="148"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Professor Dr Michael Ramharter</name_or_title>
      <organization>Medical University of Vienna, Division of Infectious Diseases and Tropical Medicine</organization>
      <phone>+43140400-44400</phone>
      <email>michael.ramharter@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

